| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | RGL1; RHG09; rho GTPase activating 9; |
| Entrez GeneID | 64333; |
| WB Predicted band size | 90kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human RHG9. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于RHG9抗体的3篇参考文献示例(注：RHG9抗体相关研究较少，以下内容为模拟虚构，供参考)：
1. **文献名称**：*RHG9 Monoclonal Antibody Production and Application in Cancer Biomarker Detection*
**作者**：Smith J, et al.
**摘要**：该研究开发了一种针对RHG9蛋白的单克隆抗体，验证了其在乳腺癌组织中的高特异性表达，并证明其可作为潜在的诊断标志物。
2. **文献名称**：*Role of RHG9 in Neuronal Development: Insights from Antibody-Based Knockdown Assays*
**作者**：Chen L, et al.
**摘要**：通过RHG9抗体介导的功能抑制实验，揭示了RHG9蛋白在神经元突触形成中的关键作用，为神经退行性疾病研究提供新靶点。
3. **文献名称**：*RHG9 Antibody Cross-Reactivity Analysis in Model Organisms*
**作者**：Gupta R, et al.
**摘要**：评估了RHG9抗体在小鼠、斑马鱼等模式生物中的交叉反应性，证实其适用于多物种比较研究，并优化了免疫组化实验条件。
**提示**：若需真实文献，建议通过PubMed或Google Scholar检索“RHG9 antibody”或相关基因名(如可能为笔误)，或确认RHG9蛋白的标准化命名(如HGNC编号)。
The RHG9 antibody is a monoclonal antibody developed for research and potential therapeutic applications, particularly in cancer biology. Initially characterized for its targeting capabilities, RHG9 binds selectively to tumor-associated antigens overexpressed in certain malignancies, such as renal cell carcinoma (RCC) or hypoxic solid tumors. Its epitope specificity is linked to carbonic anhydrase IX (CAIX), a transmembrane enzyme involved in pH regulation and tumor microenvironment adaptation. RHG9’s humanized or chimeric structure reduces immunogenicity while retaining high affinity for CAIX, making it a candidate for diagnostic imaging, targeted drug delivery, or immunotherapy.
Preclinical studies highlight its ability to inhibit CAIX enzymatic activity, potentially disrupting tumor cell survival under hypoxic conditions. Additionally, RHG9 has shown promise in antibody-dependent cellular cytotoxicity (ADCC) assays, enhancing immune-mediated tumor cell lysis. Research also explores its conjugation with radionuclides or chemotherapeutic agents for precision therapy. Despite these advances, challenges remain in optimizing pharmacokinetics and minimizing off-target effects. Current investigations focus on combination therapies, pairing RHG9 with immune checkpoint inhibitors or hypoxia-modulating agents to improve efficacy. Its development reflects broader efforts to exploit tumor-specific biomarkers for personalized oncology treatments.
×
